Abbott’s Libre Duo 10 Day has received FDA De Novo authorization as the first integrated continuous glucose and ketone monitoring system in the United States, potentially extending CGM from daily glucose control into early diabetic ketoacidosis warning.
Abbott’s investigational TactiFlex Duo dual-energy ablation catheter delivered favorable 12-month results in the FlexPulse Global IDE study, supporting the company’s effort to secure U.S. FDA approval after receiving CE Mark in Europe.
Libre Duo 10 Day continuously measures glucose and ketones every minute for people with diabetes aged two and older, creating the first US integrated glucose-ketone monitoring category.
AI can now guide coronary imaging in real time. Abbott’s Ultreon 3.0 puts precision PCI closer to routine clinical workflow.
Medtronic’s MiniMed Go earns FDA clearance. Learn how it could reshape insulin injection therapy by combining smart pens, CGM insights, and dose algorithms.
Medtronic’s MiniMed 780G now ships in the U.S. with Abbott’s Instinct sensor. Explore how this launch could reshape CGM-insulin system competition.